Otsuka units launch digital depression therapy Rejoyn in USA

Japanese mid-size drugmaker Otsuka Pharmaceuticals (TYO: 4578) says that its subsidiaries Otsuka Precision Health, Inc. (OPH) and Click Therapeutics (Click) have launched Rejoyn (developed as CT-152).

The US Food and Drug Administration (FDA) approved Rejoyn in March 2024 and it is the first-and-only prescription digital therapeutic for the treatment of major depressive disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication.

Patients can obtain a prescription for Rejoyn from their current provider or from another provider via a virtual consultation from Wheel Health, Inc., whose platform can be accessed from a link on the Rejoyn website. BlinkRx is the exclusive pharmacy provider for Rejoyn and will digitally dispense access codes for Rejoyn to prescribed patients. As a digital treatment, Rejoyn can then be downloaded from mobile application stores and used at a place and time of patients' choosing.